← All Imunon, INC filings

Imunon, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
IMNN
Imunon, INC
SCHEDULE: Armistice Capital Discloses 9.99% Stake in Imunon, Inc.
Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 450,315 shares, representing 9.99% of Imunon, Inc.'s common stock.
NASDAQ
IMNN
Imunon, INC
SCHEDULE: Armistice Capital Discloses 9.99% Stake in Imunon, Inc.
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 396,718 shares, representing 9.99% of Imunon, Inc.'s common stock, as of March 31, 2026.
NASDAQ
IMNN
Imunon, INC
SCHEDULE: Imunon Ownership Update: Ayrton Capital's 0.01% Stake
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a combined 0.01% beneficial ownership in Imunon, Inc. common stock.
NASDAQ
IMNN
Imunon, INC
SCHEDULE: Intracoastal Capital Amends Imunon Stake to 4.99%
Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Imunon, Inc. as of June 30, 2025.
NASDAQ
IMNN
Imunon, INC
SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 5.5% Passive Stake in Imunon, Inc.
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a passive beneficial ownership of 5.5% in Imunon, Inc. common stock.
NASDAQ
IMNN
Imunon, INC
SCHEDULE 13G/A: Investment Funds and Managing Member Disclose 7.9% Passive Stake in Imunon, Inc.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed a 7.9% beneficial ownership stake in Imunon, Inc., primarily through warrants.